Perimeter Medical Imaging AI, Inc. PYNKF

Company Overview

Perimeter Medical Imaging AI, Inc. is a Canadian medical technology company focused on advanced imaging tools for real-time surgical decision support, primarily in oncology. The company develops ultra-high-resolution optical imaging systems and artificial intelligence-assisted technologies intended to help surgeons identify residual cancer tissue during operations. Perimeter operates within the medical imaging, surgical oncology, and artificial intelligence-enabled healthcare technology industries, with a particular emphasis on breast cancer surgery applications.

The company’s primary commercial platform is the Perimeter S-Series OCT system, which uses optical coherence tomography (OCT) to generate cross-sectional images of excised tissue in real time at the point of care. Perimeter has also advanced AI-enabled technologies through its ImgAssist AI platform, designed to support intraoperative assessment and improve margin visualization. The company evolved from earlier OCT imaging development efforts and expanded its strategy through clinical collaborations, regulatory clearances, and AI-focused development initiatives aimed at reducing repeat surgeries and improving surgical workflow efficiency. Its positioning is differentiated by combining high-resolution imaging with machine learning tools tailored for intraoperative oncology applications.

Business Operations

Perimeter Medical Imaging AI generates revenue primarily through the commercialization and evaluation of its imaging systems, related consumables, and technology development activities. The company’s operations are centered on surgical imaging solutions used by hospitals, cancer centers, and surgeons performing breast-conserving procedures. Its core operating focus includes the development, manufacturing oversight, regulatory advancement, and clinical deployment of the Perimeter S-Series OCT platform and associated AI-enhanced imaging software.

The company operates principally in North America, with commercial and clinical activities concentrated in the United States and Canada. Perimeter maintains intellectual property related to OCT imaging, image interpretation workflows, and AI-assisted surgical assessment technologies. Strategic collaborations with clinical institutions and cancer research centers have supported validation studies and development programs. Public disclosures indicate that the company has also benefited from non-dilutive funding support connected to U.S. cancer research initiatives, including programs associated with the Cancer Prevention and Research Institute of Texas (CPRIT).

Strategic Position & Investments

Perimeter’s strategic direction has focused on expanding adoption of intraoperative imaging technologies while integrating artificial intelligence capabilities into surgical oncology workflows. A central growth initiative has been the advancement of the ImgAssist AI platform, which is intended to help clinicians identify suspicious tissue margins during surgery with greater efficiency and consistency. The company has emphasized clinical validation studies, regulatory pathway advancement, and surgeon adoption as key components of its commercialization strategy.

The company’s investments have primarily centered on product development, AI algorithm training, clinical studies, and regulatory activities rather than large-scale acquisitions. Perimeter has targeted the broader precision surgery and image-guided oncology markets, where demand for improved margin assessment technologies continues to grow. Its strategic positioning is tied to the potential reduction of repeat surgeries in breast-conserving procedures, an area that remains a significant clinical and economic challenge. Publicly available information does not indicate material diversified subsidiary holdings beyond its core imaging and AI operations.

Geographic Footprint

Perimeter Medical Imaging AI is headquartered in Toronto, Canada, with substantial operational and commercial engagement in the United States healthcare market. The company’s imaging systems and clinical programs have primarily targeted U.S. hospitals, surgical centers, and oncology institutions due to the scale of the U.S. breast cancer treatment market and associated regulatory opportunities.

The company’s market presence remains concentrated in North America, although its technologies are relevant to broader international surgical oncology markets. Regulatory clearances, clinical collaborations, and commercialization activities have largely been associated with U.S.-based institutions and healthcare providers. Available public disclosures do not indicate significant large-scale commercial operations outside North America as of recent reporting periods.

Leadership & Governance

Perimeter Medical Imaging AI is led by executives with backgrounds in medical technology, commercialization, healthcare operations, and corporate finance. Leadership has emphasized advancing AI-enabled surgical imaging technologies, strengthening clinical evidence generation, and expanding commercialization efforts in oncology-focused healthcare settings.

Key executives and leadership figures include:

• Adrian Mendes – Chief Executive Officer
• Jeremy Sobotta – Chief Financial Officer
• Dr. Robert Y. Kerbel – Scientific and Medical Advisory leadership contributor
• Tom Boon – Board and strategic leadership involvement through historical governance roles

The company’s governance approach has emphasized clinical validation, regulatory compliance, capital discipline, and strategic development of imaging technologies intended to support precision surgery initiatives. Public company disclosures, including filings on Canadian securities platforms and OTC market materials, indicate ongoing focus on long-term commercialization and AI-assisted surgical innovation.